期刊文献+

氯沙坦治疗轻、中度原发性高血压并高尿酸血症的临床观察 被引量:1

下载PDF
导出
摘要 目的观察氯沙坦治疗轻中度原发性高血压并高尿酸血症的降压效果及对尿酸的影响。方法将轻、中度原发性高血压并高尿酸血症患者85例随机分成两组,氯沙坦组(43例)和缬沙坦组(42例),观察治疗4周、8周末血压及血尿酸浓度的变化。结果85例患者有83例完成观察过程。氯沙坦组42例,缬沙坦组41例,血压与治疗前比较,两组治疗4周、8周末收缩压和舒张压均有明显降低(P<0.05);两组间血压比较,治疗4周、8周末收缩压和舒张压差异无统计学意义(P>0.05);血尿酸浓度与治疗前比较,氯沙坦组治疗4周、8周末明显降低(P<0.05),缬沙坦组则无明显降低(P>0.05);两组间血尿酸比较,治疗4周、8周末血尿酸浓度氯沙坦组明显低于缬沙坦组(P<0.05)。结论氯沙坦和缬沙坦治疗轻、中度高血压均能有效控制血压,而氯沙坦还能有效降低血尿酸,故对轻、中度原发性高血压并高尿酸血症患者用氯沙坦治疗是种理想的选择。
作者 蒋连保
出处 《右江医学》 2009年第3期267-268,共2页 Chinese Youjiang Medical Journal
  • 相关文献

参考文献7

  • 1Jnhnson RJ,kang DH,FeigD,et al.Is there a pathngenetic role far uric acid in hypertension and cardiovascular and renal disease[J].Hypertension 2003,41:1183-1190.
  • 2Hoieggen A,Alderman MH,Kjeldsen SE,et al.The impact of serum uric acid on cardiovascular outcomes in the LIFE study[J].Kidney Int,2004,65:1041-1049.
  • 3叶任高.内科学[M] 第5版[M].北京:人民卫生出版社,2001.294-307.
  • 4Hare Jm,Jobnson RJ.Urie acid predicts clinical nutcomes in heant failure,lnsights regar ding the role of xanthine oxidase and uric acid in disease pathophysiolohy[J].Ciraclation,2003,107 (15):1951-1953.
  • 5Nokashima M,UematsuT,KosugeK,et al.Pilot study nf the uricnsuric effect of DuP-753,a new angintensin Ⅱ receptor antagonist,in healthy subjects[J].Eur J clin pharmacnl,1992,42:333-335.
  • 6党爱民,刘国仗,张宇辉,陈改玲.血管紧张素Ⅱ受体拮抗剂干预高血压患者尿酸代谢的对比研究[J].中华心血管病杂志,2006,34(10):882-885. 被引量:59
  • 7李艳萍.氯沙坦、缬沙坦联合氨氯地平治疗原发性高血压并高尿酸血症的对比研究[J].南华大学学报(医学版),2007,35(3):404-406. 被引量:17

二级参考文献20

  • 1党爱民,刘国仗,张宇辉,陈改玲.血管紧张素Ⅱ受体拮抗剂干预高血压患者尿酸代谢的对比研究[J].中华心血管病杂志,2006,34(10):882-885. 被引量:59
  • 2Moriarity JT,Folsom AR,Iribarren C,et al.Serum uric acid and risk of coronary heart disease:Atherosclerosis Risk in Communities(ARIC) Study.Ann Epidemiol,2000,10:136-143.
  • 3Breckenridge A.Hypertension and hyperuricaemia.Lancet,1966,1:15-18.
  • 4Cannon PJ,Stason WB,demartini FE,et al.Hyperurcemia in primary and renal hypertension.N Engl J Med,1966,275:457-464
  • 5Johnson RJ,Kang DH,Feig D,et al.Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease.?Hypertension,2003,41:1183-1190.
  • 6Hoieggen A,Alderman MH,Kjeldsen SE,et al.The impact of serum uric acid on cardiovascular outcomes in the LIFE study.Kidney Int,2004,65:1041-1049.
  • 7孟昭亨.尿酸与痛风.见:方圻,主编.现代内科学.北京:人民军医出版社,1995.2868-2878.
  • 8Nakashima M,Uematsu T,Kosuge K,et al.Pilot study of the uricosuric effect of DuP-753,a new angiotensin Ⅱ receptor antagonist,in healthy subjects.Eur J Clin Pharmacol,1992,42:333-335.
  • 9Sweet CS,Bradstreet DC,Berman RS,et al.Pharmacodynamic activity of intravenous E-3174,an angiotensin Ⅱ antagonist,in patients with essential hypertension.Am J Hypertens,1994,7:1035 -1040.
  • 10Wurzner G,Gester JC,Chiolero A,et al.Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.J Hypertens,2001,19:1855-1860.

共引文献244

同被引文献19

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部